Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome (ANISE-II)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05383677 |
Recruitment Status :
Recruiting
First Posted : May 20, 2022
Last Update Posted : December 19, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sjogren's Syndrome | Drug: Anifrolumab Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | ANIfrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome - Efficacy and Safety Assessment in a Randomized, Double-blind, Placebo-controlled Phase-IIa Proof-of-concept Trial (ANISE-II) |
Actual Study Start Date : | October 1, 2022 |
Estimated Primary Completion Date : | May 1, 2024 |
Estimated Study Completion Date : | August 1, 2024 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Anifrolumab
20 patients will receive anifrolumab treatment
|
Drug: Anifrolumab
Anifrolumab 300 mg will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
Other Name: Saphnelo |
Placebo Comparator: Placebo
10 patients will receive placebo treatment
|
Drug: Placebo
Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks. |
- Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS) response [ Time Frame: Week 24 ]The CRESS is a recently developed composite endpoint which consists of five clinically relevant items for pSS: a systemic disease activity, patient-reported symptoms, tear gland, salivary gland and serology item. A CRESS responder is someone who reached response on at least three out of five items (Arends et al., https://doi.org/10.1016/S2665-9913(21)00122-3)
- Safety (adverse events and tolerability) [ Time Frame: Weeks 0, 4, 8, 12, 16, 20 and 24 ]Adverse events and tolerability
- Total CRESS response [ Time Frame: Week 12 ]The CRESS is a recently developed composite endpoint which consists of five clinically relevant items for pSS: a systemic disease activity, patient-reported symptoms, tear gland, salivary gland and serology item. A CRESS responder is someone who reached response on at least three out of five items (Arends et al., https://doi.org/10.1016/S2665-9913(21)00122-3)
- ClinESSDAI [ Time Frame: Weeks 0, 8, 12, 20, 24 ]Change in ClinESSDAI from baseline, scale 0-135. A higher score means a worse outcome.
- ESSPRI [ Time Frame: Weeks 0, 8, 12, 20, 24 ]Change in ESSPRI from baseline, scale 0-10. A higher score means a worse outcome.
- Schirmer's test [ Time Frame: Weeks 0, 12, 24 ]Change in Schirmer's test from baseline, scale 0-35 mm. A higher score means a better outcome.
- Ocular Staining Score (OSS) [ Time Frame: Weeks 0, 12, 24. ]Change in OSS from baseline, scale 0-12. A higher score means a worse outcome
- Salivary gland ultrasonography (SGUS) [ Time Frame: SGUS: weeks 0, 12, 24 ]Change in total Hocevar score (0-48) from baseline. A higher score means a worse outcome.
- Rheumatoid factor (RF) [ Time Frame: Weeks 0, 8, 12, 20, 24 ]Change in RF (IU/ml) from baseline. A higher score means a worse outcome.
- Total IgG [ Time Frame: Weeks 0, 8, 12, 20, 24 ]Change in IgG (g/L) from baseline. A higher score means a worse outcome.
- Unstimulated whole salivary secretion (UWS) [ Time Frame: Weeks 0, 12, 24. ]Change in UWS (reported in ml/min) from baseline. A higher score means a better outcome.
- ESSDAI [ Time Frame: Weeks 0, 8, 12, 20, 24 ]Change in ESSDAI from baseline, scale 0-123. A higher score means a worse outcome.
- (Clin)ESSDAI minimal clinically important improvement (MCII) [ Time Frame: Weeks 8, 12, 20, 24 ](Clin)ESSDAI MCII is defined as a decrease of ≥3 points
- (Clin)ESSDAI low disease activity [ Time Frame: Weeks 8, 12, 20, 24 ](Clin)ESSDAI low disease activity is defined as a score<5
- Physician GDA (PhGDA) [ Time Frame: Weeks 0, 8, 12, 20, 24 ]Change in PhGDA from baseline, scale 0-10. A higher score means a worse outcome.
- NRS score oral, ocular and vaginal dryness [ Time Frame: Weeks 0, 8, 12, 20, 24 ]Change in NRS score from baseline, scale 0-10. A higher score means a worse outcome.
- Patient GDA (PtGDA) [ Time Frame: Weeks 0, 8, 12, 20, 24 ]Change in PtGDA from baseline, scale 0-10. A higher score means a worse outcome.
- Short Form-36 (SF-36) health survey [ Time Frame: Weeks 0, 12, 24 ]The SF-36 includes 8 domains, each ranging on a scale from 0-100. A higher score means a better outcome.
- EurQoL 5 dimensions (EQ-5D) measure of health-related quality of life [ Time Frame: Weeks 0, 8, 12, 20, 24 ]The EQ-5D is reported as index value (0-1). A higher score means a better outcome.
- Multidimensional Fatigue Index (MFI) scale [ Time Frame: Weeks 0, 12, 24 ]The MFI is reported on a scale of 4-20 for both physical and mental fatigue. A higher score means a worse outcome.
- Female Sexual Function Index (FSFI) in females [ Time Frame: Weeks 0, 12, 24 ]The FSFI total score has a range of 2-36. A higher score indicates better outcome.
- SGUS OMERACT score [ Time Frame: Weeks 0, 12, 24 ]The OMERACT score is reported on a scale of 0-3. A higher score means a worse outcome.
- Parotid gland histology: focus score [ Time Frame: Week 0, 24 ]Number of foci / 4 mm2
- Parotid gland histology: area of CD45 infiltrate [ Time Frame: Week 0, 24 ]Change in are of CD45 infiltrate at week 24 compared to week 0
- Serum levels of anti-SSA/SSB [ Time Frame: Weeks 0, 8, 12, 20, 24 ]U/ml
- Complement (C3/C4) [ Time Frame: Weeks 0, 8, 12, 20, 24 ]g/L
- Lymphocyte count [ Time Frame: Weeks 0, 8, 12, 20, 24 ]10^9/L
- Presence of cryoglobulinemia [ Time Frame: Weeks 0, 12, 24 ]Presence of cryoglobulinemia (yes/no) will be analysed at week 0, 12 and 24.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent
- Female or male aged ≥18 years
- Disease duration (time since diagnosis) ≤10 years. In case of pediatric-onset pSS a disease duration of ≤15 years is allowed if there is residual gland function (UWS≥0.01 or SWS≥0.1 ml/min).
- Fulfilment of 2016 ACR-EULAR classification criteria for pSS (which includes focus score ≥1 in salivary gland biopsy and/or anti-SSA/Ro positivity), based on previous diagnostic examinations
- Presence of anti-SSA antibodies
- ESSDAI≥5 and/or ESSPRI≥5. ESSDAI≥5 implicates a moderate to high systemic disease activity and ESSPRI≥5 implicates that the patient-reported symptom state is unacceptable. At least 50% of patients need to fulfil the ESSDAI≥5 criterion. Inclusion of patients with low ESSDAI (<5) should be discontinued when 15 included patients (50%) have a low ESSDAI.
- Willingness to undergo a repeated parotid gland biopsy at baseline and 24 weeks after start treatment. If a recent parotid gland biopsy (within ≤1 year before the baseline visit) is available, and enough material of this parotid gland biopsy is available, this biopsy can be used as baseline sample.
- Use of reliable method of contraception for participants of reproductive potential.
- Vaccinated against COVID-19 (at least two COVID-19 vaccinations) or previous confirmed COVID-19 infection (from which the patient is recovered) in combination with at least one COVID-19 vaccination or a previous confirmed COVID-19 infection (from which the patients has recovered) in combination with a positive anti-SARS-CoV-2 antibody test.
Exclusion Criteria:
- Presence of any other connective tissue disease
- Positive pregnancy test (urinary HCG) at screening or breast-feeding
- History of alcohol or drug abuse
- History of malignancy or with a current suspicion for cancer, apart from local MALT lymphoma, squamous or basal cell carcinoma of the skin treated with documented success of curative therapy ≥3 months prior to week 0 or cervical cancer in situ treated with apparent success with curative therapy ≥1 year prior to week 0.
- Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of HIV which will be tested during screening.
- History of chronic or recurrent serious infections. (e.g. chronic pyelonephritis, osteomyelitis or bronchiectasis).
- Subjects with serious bacterial infections within the last 3 months, unless treated and resolved with antibiotics.
- Opportunistic infection requiring hospitilization or IV antimicrobial treatment within 3 years of randomization
- Any infection requiring hospitalization or treatment with IV anti-infective medications not completed at least 4 weeks prior to signing the ICF.
- Subjects with herpes zoster that resolved less than 12 weeks before potential enrollment or any severe case of herpes zoster in a subjects history, including, but not limited to, non-cutaneous herpes (ever), herpes encephalitis (ever), recurrent herpes zoster (defined as 2 episodes within 2 years) or ophthalmic herpes involving the retina (ever).
- Any clinical cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection that has not completely resolved within 12 weeks prior to signing the ICF.
- Any history of severe COVID-19 infection (e.g. requiring hospitalization, ICU care or assisted ventilation) or any prior COVID-19 infection with unresolved sequelae. Any acute COVID-19 infection (lab confirmed or suspected based on clinical symptoms) within the last 3 months prior to screening.
- Subjects at risk for TB. Specifically excluded from this study will be subjects with a history of active TB; current clinical, radiographic, or laboratory evidence of active TB, which will be tested during screening; history of latent TB, with the exception of latent TB with documented completion of appropriate treatment.
- Subjects who are positive for hepatitis B surface antigen, which will be tested during screening.
- Subjects who are positive for hepatitis C antibody if the presence of hepatitis C virus was also shown with polymerase chain reaction or recombinant immunoblot assay, which will be tested during screening.
- Subjects who have received any live or attenuated vaccines within 8 weeks prior to signing the ICF.
- Blood transfusion or receipt of blood products within 4 weeks prior to signing the ICF.
- Underlying cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal, hematological or neurological conditions, chronic or latent infectious diseases or immune deficiency which places the patient at an unacceptable risk for participation in the study.
- Preceding treatment with biological DMARDs, including abatacept, anti-TNF or other monoclonal antibodies within 6 months, and rituximab within 12 months from baseline
- Use of high-dose prednisone, less than 2 weeks before inclusion. Stable low dose (≤10 mg) is allowed.
- Use of hydroxychloroquine, methotrexate, cyclophosphamide, cyclosporine, azathioprine, MMF and leflunomide less than 3 months ago.
- Use of pilocarpine less than 1 month ago.
-
Lab abnormalities:
- Serum creatinine > 2.8 mg/dl (250 μmol/l)
- ASAT or ALAT outside 2.5 x upper normal range of the laboratory
- Hb < 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females
- Neutrophil granulocytes less than 0.5 x 109/l
- Platelet count less than 50 x 109/l
- Any other laboratory test results that, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study.
- A known history of allergy or reaction to any component of the IP formulation or history of anaphylaxis to any human gamma globuline therapy.
- Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site)
- Previous enrolment or randomisation in the present study
- Participation in another clinical study with an investigational drug during the last 6 months, or local investigational product during the last month
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05383677
Contact: Hendrika Bootsma | +315036129456 | h.bootsma@umcg.nl |
Netherlands | |
University Medical Centre Groningen | Recruiting |
Groningen, Netherlands | |
Contact: Hendrika Bootsma h.bootsma@umcg.nl |
Principal Investigator: | Hendrika Bootsma | University Medical Center Groningen |
Responsible Party: | University Medical Center Groningen |
ClinicalTrials.gov Identifier: | NCT05383677 |
Other Study ID Numbers: |
ESR-21-21284 2022-000609-28 ( EudraCT Number ) |
First Posted: | May 20, 2022 Key Record Dates |
Last Update Posted: | December 19, 2022 |
Last Verified: | December 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Sjogren's Syndrome Syndrome Disease Pathologic Processes Arthritis, Rheumatoid Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Xerostomia |
Salivary Gland Diseases Mouth Diseases Stomatognathic Diseases Dry Eye Syndromes Lacrimal Apparatus Diseases Eye Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |